JP2017500297A - クライオミリングによる粉末状医薬組成物の調製 - Google Patents
クライオミリングによる粉末状医薬組成物の調製 Download PDFInfo
- Publication number
- JP2017500297A JP2017500297A JP2016534227A JP2016534227A JP2017500297A JP 2017500297 A JP2017500297 A JP 2017500297A JP 2016534227 A JP2016534227 A JP 2016534227A JP 2016534227 A JP2016534227 A JP 2016534227A JP 2017500297 A JP2017500297 A JP 2017500297A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- additive
- extruder
- mill
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 89
- 238000009646 cryomilling Methods 0.000 title description 24
- 238000002360 preparation method Methods 0.000 title description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 187
- 238000000034 method Methods 0.000 claims abstract description 90
- 239000000203 mixture Substances 0.000 claims abstract description 80
- 239000004615 ingredient Substances 0.000 claims abstract description 69
- 229920001515 polyalkylene glycol Polymers 0.000 claims abstract description 40
- 238000000227 grinding Methods 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 25
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 166
- 229940087168 alpha tocopherol Drugs 0.000 claims description 81
- 229960000984 tocofersolan Drugs 0.000 claims description 81
- 239000002076 α-tocopherol Substances 0.000 claims description 81
- 235000004835 α-tocopherol Nutrition 0.000 claims description 81
- 239000002202 Polyethylene glycol Substances 0.000 claims description 62
- 229920001223 polyethylene glycol Polymers 0.000 claims description 62
- 239000000463 material Substances 0.000 claims description 60
- 239000000306 component Substances 0.000 claims description 57
- 238000002844 melting Methods 0.000 claims description 55
- 230000008018 melting Effects 0.000 claims description 55
- 239000002245 particle Substances 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 33
- 239000007788 liquid Substances 0.000 claims description 31
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 17
- 238000003801 milling Methods 0.000 claims description 15
- 238000011144 upstream manufacturing Methods 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 12
- 239000005426 pharmaceutical component Substances 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 10
- 230000002209 hydrophobic effect Effects 0.000 claims description 9
- 229930003799 tocopherol Natural products 0.000 claims description 5
- 239000011732 tocopherol Substances 0.000 claims description 5
- 235000010384 tocopherol Nutrition 0.000 claims description 5
- 229960001295 tocopherol Drugs 0.000 claims description 5
- 239000000084 colloidal system Substances 0.000 claims description 4
- 230000035939 shock Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 2
- 230000000717 retained effect Effects 0.000 claims description 2
- 125000001020 α-tocopherol group Chemical group 0.000 claims 1
- 238000001125 extrusion Methods 0.000 description 47
- 239000013543 active substance Substances 0.000 description 25
- 239000000654 additive Substances 0.000 description 23
- 239000002552 dosage form Substances 0.000 description 22
- 239000007921 spray Substances 0.000 description 20
- 238000009826 distribution Methods 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- 230000015271 coagulation Effects 0.000 description 15
- 238000005345 coagulation Methods 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000013461 design Methods 0.000 description 8
- 230000000996 additive effect Effects 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
- 238000004898 kneading Methods 0.000 description 6
- 229940046009 vitamin E Drugs 0.000 description 6
- 235000019165 vitamin E Nutrition 0.000 description 6
- 239000011709 vitamin E Substances 0.000 description 6
- 239000008118 PEG 6000 Substances 0.000 description 4
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000009827 uniform distribution Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000004497 NIR spectroscopy Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 229960000878 docusate sodium Drugs 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- -1 glidants Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000002706 dry binder Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000011796 hollow space material Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 238000009740 moulding (composite fabrication) Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000005029 sieve analysis Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002704 solution binder Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 description 1
- 229960005126 tapentadol Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C19/00—Other disintegrating devices or methods
- B02C19/18—Use of auxiliary physical effects, e.g. ultrasonics, irradiation, for disintegrating
- B02C19/186—Use of cold or heat for disintegrating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
- B02C17/18—Details
- B02C17/1815—Cooling or heating devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C23/00—Auxiliary methods or auxiliary devices or accessories specially adapted for crushing or disintegrating not provided for in preceding groups or not specially adapted to apparatus covered by a single preceding group
- B02C23/08—Separating or sorting of material, associated with crushing or disintegrating
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C7/00—Crushing or disintegrating by disc mills
- B02C7/11—Details
- B02C7/17—Cooling or heating of discs
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B7/00—Mixing; Kneading
- B29B7/02—Mixing; Kneading non-continuous, with mechanical mixing or kneading devices, i.e. batch type
- B29B7/06—Mixing; Kneading non-continuous, with mechanical mixing or kneading devices, i.e. batch type with movable mixing or kneading devices
- B29B7/10—Mixing; Kneading non-continuous, with mechanical mixing or kneading devices, i.e. batch type with movable mixing or kneading devices rotary
- B29B7/18—Mixing; Kneading non-continuous, with mechanical mixing or kneading devices, i.e. batch type with movable mixing or kneading devices rotary with more than one shaft
- B29B7/20—Mixing; Kneading non-continuous, with mechanical mixing or kneading devices, i.e. batch type with movable mixing or kneading devices rotary with more than one shaft with intermeshing devices, e.g. screws
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B9/00—Making granules
- B29B9/10—Making granules by moulding the material, i.e. treating it in the molten state
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B9/00—Making granules
- B29B9/12—Making granules characterised by structure or composition
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B9/00—Making granules
- B29B9/16—Auxiliary treatment of granules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B9/00—Making granules
- B29B9/12—Making granules characterised by structure or composition
- B29B2009/125—Micropellets, microgranules, microparticles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2071/00—Use of polyethers, e.g. PEEK, i.e. polyether-etherketone or PEK, i.e. polyetherketone or derivatives thereof, as moulding material
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mechanical Engineering (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Disintegrating Or Milling (AREA)
Abstract
Description
(c)上記医薬添加剤および上記医薬成分の混合物を周囲温度より低い温度で粉砕するステップ、
を含む方法。
(c)上記医薬添加剤および上記医薬成分の混合物を周囲温度より低い温度で粉砕するステップ、
を含む方法に関する。
−前記医薬添加剤、好ましくは第1の医薬添加剤は、ポリマー、より好ましくは線状ポリマーであり、さらに好ましくは水溶性ポリマー、より一層好ましくはポリアルキレングリコール、最も好ましくはポリエチレングリコールであり;および/または
−前記医薬成分、好ましくは第2の医薬添加剤は、酸化防止剤、好ましくはトコフェロール成分、より好ましくはα−トコフェロールである。
(b)医薬添加剤、好ましくは第1の医薬添加剤(ポリアルキレングルコールであり、より好ましくはポリエチレングリコールである)と、医薬成分、好ましくは第2の医薬添加剤、より好ましくはα−トコフェロールとの混合物を、上記混合物の液体溶融物が押出機において凝固でき、粉末の形態で押出機を出ることができる温度プロファイルで、押出機において押出すステップ。
−T1は、医薬添加剤、好ましくは第1の医薬添加剤(これはポリアルキレングリコール、より好ましくはポリエチレングリコールである)、および/または医薬成分、好ましくは第2の医薬添加剤、より好ましくはα−トコフェロール、および/または任意選択的に存在する第3構成成分の融点/溶融域より大きく;および/または
−T2は、医薬添加剤、好ましくは第1の医薬添加剤(これはポリアルキレングリコール、より好ましくはポリエチレングリコールである)、および/または医薬成分、好ましくは第2の医薬添加剤、より好ましくはα−トコフェロール、および/または任意選択的に存在する第3構成成分の融点/溶融域未満である。
−T1は、25℃〜115℃、または30℃〜110℃、より好ましくは35℃〜105℃、または40℃〜100℃、さらに好ましくは45℃〜95℃、または50℃〜90℃、より一層好ましくは55℃〜85℃、最も好ましくは60℃〜80℃、特に65℃〜75℃の範囲内であり;および/または
−T2は、−20℃〜50℃、より好ましくは−10℃〜40℃、さらに好ましくは−5℃〜35℃、より一層好ましくは0℃〜30℃、最も好ましくは5℃〜25℃、特に10℃〜20℃の範囲内である。
(a)医薬添加剤、好ましくは第1の医薬添加剤(これはポリアルキレングリコール、より好ましくはポリエチレングリコールである)を、医薬成分、好ましくは第2の医薬添加剤、より好ましくはα−トコフェロール、および任意選択的に存在する第3構成成分と、押出機の外で混合し、次いで得られた混合物を押出機中に供給するステップ、または
医薬添加剤、好ましくは第1の医薬添加剤(これはポリアルキレングリコール、より好ましくはポリエチレングリコールである)、および医薬成分、好ましくは第2の医薬添加剤、より好ましくはα−トコフェロール、および任意選択的に存在する第3構成成分を、異なるフィーディングポイントで押出機中に供給するステップ、ここで、医薬添加剤、好ましくは第1の医薬添加剤(これはポリアルキレングリコール、より好ましくはポリエチレングリコールである)のためのフィーディングポイントは、医薬成分、好ましくは第2の医薬添加剤、より好ましくはα−トコフェロールのためのフィーディングポイントに対して上流に位置しているか、または逆もしかりである。
(d)粉末を選別するステップ。
−薬理学的に活性な物質、好ましくはオピオイド、および/または
−好ましくは少なくとも200,000g/mol、より好ましくは少なくとも500,000g/mol、さらに好ましくは少なくとも750,000g/mol、より一層好ましくは少なくとも1,000,000g/molの、特に1,000,000g/mol〜10,000,000g/molの範囲内の重量平均分子量を有する、高分子量ポリアルキレンオキシド、好ましくはポリエチレンオキシド;および/または
−セルロースエーテル、好ましくはヒドロキシプロピルメチルセルロースまたはヒドロキシプロピルセルロース、
と一緒に含む、粉末状医薬組成物を製剤化するステップを含む。
α−トコフェロール−ポリエチレングリコール6000プレブレンドを、二軸スクリュー押出機Leistritz ZSE27タイプにより製造した。
・Hosokawa−Alpine(ドイツ)(例2)
・Nuova Guseo(イタリア)(例3)
例2−プレブレンドのクライオミリング− Hosokawa−Alpine:
微細な粉末状医薬組成物を得るために、α−トコフェロール/PEGを含む例1のプレブレンドを、引き続きクライオミリングに付した。
実施例1のプレブレンド材料を、スロットルフィーディングデバイスに仕込んだ。上記材料を液体窒素と接触させ、脆化させた。冷却した材料を、回転プレートビーターならびに0.5および0.8mmの篩を備えた粉砕系に落下させた。
4.1 例2および3で得られたクライオミリングで粉砕されたブレンドをそれぞれ、薬剤生成物製剤の他の成分とブレンドした。上記ブレンド内のα−トコフェロールの含量均一性および物理的特性(すなわち流動性、密度、流動分布(PSD))を調べた。
以下を用いる3つのブレンディングトライアル(同一の質および量の組成物):
リファレンス 14%α−トコフェロール/PEG 市販のブレンド
14%α−トコフェロール/PEG材料(Hosokawa製によりクライオミリングで粉砕した、例2)
14%α−トコフェロール/PEG材料(Nuova Guseo製によりクライオミリングで粉砕した、例3)
全体のバッチサイズは48kgであった。
Claims (15)
- 医薬添加剤および医薬成分を含み、上記医薬添加剤がポリアルキレングリコールである粉末状の医薬組成物を製造する方法であって;
(c)上記医薬添加剤および上記医薬成分の混合物を周囲温度より低い温度で粉砕するステップ、
を含む方法。 - 上記の周囲温度より低い温度が最大で−10℃である、請求項1に記載の方法。
- ステップ(c)が、冷却系と、粉砕される材料に機械的衝撃を付与するための手段を含むミリングチャンバーとを備えるクライオミルにより行われる、請求項1または2に記載の方法。
- 上記クライオミルが、所望の粒度の材料がミリングチャンバーを出ることを可能にするが、より粗い材料はミリングチャンバー内に保持する篩を備えている、請求項3に記載の方法。
- 上記クライオミルが、ボールミル、コロイドミル、コニカルミル、ディスインテグレーター、ディスクミル、エッジミル、製粉ミル、ハンマーミル、ジェットミル、ペレットミル、遊星ミル、プレートミル、撹拌ミルおよび振動ミルからなる群から選択される、請求項3または4に記載の方法。
- 以下の先行ステップ:
(b)上記医薬添加剤と上記医薬成分との混合物を、上記混合物の液体溶融物が押出機において凝固でき、粉末の形態で押出機を出ることができる温度プロファイルで、押出機において押し出すステップ、
を含む、請求項1〜5のいずれか1つに記載の方法。 - 以下の先行ステップ:
(a)上記医薬添加剤を上記医薬成分と押出機の外で混合し、次いで得られた混合物を押出機中に供給するステップ、あるいは
上記医薬添加剤および上記医薬成分を、異なるフィーディングポイントで押出機中に供給するステップ、ここで、上記医薬添加剤のためのフィーディングポイントは、上記医薬成分のためのフィーディングポイントに対して上流に位置しているか、またはその逆である、
を含む、請求項6に記載の方法。 - ステップ(a)において、上記医薬成分を、溶融した医薬添加剤に溶解するか、またはその逆である、請求項7に記載の方法。
- 以下の後続ステップ:
(d)粉末を選別するステップ、
を含む、請求項1〜8のいずれか1つに記載の方法。 - ステップ(b)において上記温度プロファイルが、温度T1〜温度T2への温度勾配を含み、ここでT1>T2であり、そして、
−T1は、上記医薬添加剤および/または上記医薬成分の融点/溶融域より高く;および/または
−T2は、上記医薬添加剤および/または上記医薬成分の融点/溶融域より低い、
請求項6〜9のいずれか1つに記載の方法。 - 上記粉末状医薬組成物が最大で100μmの平均粒度を有する、請求項1〜10のいずれか1つに記載の方法。
- 上記医薬添加剤が親水性であり、上記医薬成分が疎水性であるか、またはその逆である、請求項1〜11のいずれか1つに記載の方法。
- 上記医薬成分が第2の医薬添加剤である、請求項1〜12のいずれか1つに記載の方法。
- −上記ポリアルキレングリコールがポリエチレングリコールであり、および/または
−上記の第2の医薬添加剤がα−トコフェロールである、
請求項13に記載の方法。 - ポリアルキレングリコールとトコフェロール成分との相対重量比が、1000:1〜5:1の範囲内である、請求項14に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13425151.1 | 2013-11-26 | ||
EP13425151 | 2013-11-26 | ||
PCT/EP2014/075618 WO2015078891A1 (en) | 2013-11-26 | 2014-11-26 | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017500297A true JP2017500297A (ja) | 2017-01-05 |
JP6480936B2 JP6480936B2 (ja) | 2019-03-13 |
Family
ID=49958218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016534227A Active JP6480936B2 (ja) | 2013-11-26 | 2014-11-26 | クライオミリングによる粉末状医薬組成物の調製 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10449547B2 (ja) |
EP (1) | EP3073994A1 (ja) |
JP (1) | JP6480936B2 (ja) |
CN (1) | CN105934241B (ja) |
AU (1) | AU2014356581C1 (ja) |
BR (1) | BR112016010482B1 (ja) |
CA (1) | CA2931553C (ja) |
HK (1) | HK1224189A1 (ja) |
IL (1) | IL245137B (ja) |
MX (1) | MX371372B (ja) |
WO (1) | WO2015078891A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018172288A (ja) * | 2017-03-31 | 2018-11-08 | ライオン株式会社 | 粉砕物及び錠剤の製造方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7082067B2 (ja) * | 2016-05-13 | 2022-06-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 溶融押出用途のためのポリマーの粒子サイズおよび分布 |
WO2019217759A1 (en) * | 2018-05-09 | 2019-11-14 | Amtek Research International Llc | Acid stratification mitigation, electrolytes, devices, and methods related thereto |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000513333A (ja) * | 1996-05-14 | 2000-10-10 | アルカームズ コントロールド セラピューティックス,インコーポレイテッド | ポリマーを基剤とした制御された放出デバイスの製造方法 |
JP2004143071A (ja) * | 2002-10-23 | 2004-05-20 | Hosokawa Funtai Gijutsu Kenkyusho:Kk | 薬物含有複合粒子の製造方法および薬物含有複合粒子 |
WO2011059074A1 (ja) * | 2009-11-13 | 2011-05-19 | 森六ケミカルズ株式会社 | 微粉末の製造方法および同方法で製造された微粉末 |
WO2013025449A1 (en) * | 2011-08-16 | 2013-02-21 | Merck Sharp & Dohme Corp. | Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions |
JP2013155124A (ja) * | 2012-01-30 | 2013-08-15 | Moriroku Chemicals Co Ltd | 医薬品の原末及びその製造方法 |
Family Cites Families (560)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2524855A (en) | 1950-10-10 | Process for the manufacture of | ||
CA722109A (en) | 1965-11-23 | W. Mock Henry | Extrusion of ethylene oxide polymers | |
US2806033A (en) | 1955-08-03 | 1957-09-10 | Lewenstein | Morphine derivative |
US2987445A (en) | 1958-10-10 | 1961-06-06 | Rohm & Haas | Drug composition |
US3370035A (en) | 1961-06-23 | 1968-02-20 | Takeda Chemical Industries Ltd | Stabilization of polyalkylene oxide |
US3332950A (en) | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
GB1147210A (en) | 1965-06-30 | 1969-04-02 | Eastman Kodak Co | Improvements in or relating to vitamins |
US3652589A (en) | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
US3806603A (en) | 1969-10-13 | 1974-04-23 | W Gaunt | Pharmaceutical carriers of plasticized dried milled particles of hydrated cooked rice endosperm |
CH503520A (de) * | 1969-12-15 | 1971-02-28 | Inventa Ag | Verfahren zum Vermahlen von körnigen Materialien, insbesondere von Kunststoffgranulaten, bei tiefen Temperaturen |
DE2210071A1 (de) | 1971-03-09 | 1972-09-14 | PPG Industries Inc., Pittsburgh, Pa. (V.StA.) | Verfahren zum Auftragen und Härten einer Vielzahl von Überzügen |
US3865108A (en) | 1971-05-17 | 1975-02-11 | Ortho Pharma Corp | Expandable drug delivery device |
US3966747A (en) | 1972-10-26 | 1976-06-29 | Bristol-Myers Company | 9-Hydroxy-6,7-benzomorphans |
US4014965A (en) | 1972-11-24 | 1977-03-29 | The Dow Chemical Company | Process for scrapless forming of plastic articles |
US3980766A (en) | 1973-08-13 | 1976-09-14 | West Laboratories, Inc. | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
US3941865A (en) | 1973-12-10 | 1976-03-02 | Union Carbide Corporation | Extrusion of ethylene oxide resins |
US4002173A (en) | 1974-07-23 | 1977-01-11 | International Paper Company | Diester crosslinked polyglucan hydrogels and reticulated sponges thereof |
DE2530563C2 (de) | 1975-07-09 | 1986-07-24 | Bayer Ag, 5090 Leverkusen | Analgetische Arzneimittel mit vermindertem Mißbrauchspotential |
JPS603286B2 (ja) | 1977-03-03 | 1985-01-26 | 日本化薬株式会社 | 定速溶出性製剤 |
US4207893A (en) | 1977-08-29 | 1980-06-17 | Alza Corporation | Device using hydrophilic polymer for delivering drug to biological environment |
US4175119A (en) | 1978-01-11 | 1979-11-20 | Porter Garry L | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs |
DE2822324C3 (de) | 1978-05-22 | 1981-02-26 | Basf Ag, 6700 Ludwigshafen | Herstellung von Vitamin-E-Trockenpulver |
US4211681A (en) | 1978-08-16 | 1980-07-08 | Union Carbide Corporation | Poly(ethylene oxide) compositions |
US4200704A (en) | 1978-09-28 | 1980-04-29 | Union Carbide Corporation | Controlled degradation of poly(ethylene oxide) |
NO793297L (no) | 1978-10-19 | 1980-04-22 | Mallinckrodt Inc | Fremgangsmaate til fremstilling av oksymorfon |
US4258027A (en) | 1979-03-26 | 1981-03-24 | Mead Johnson & Company | Multi-fractionable tablet structure |
US4215104A (en) | 1979-03-26 | 1980-07-29 | Mead Johnson & Company | Multi-fractionable tablet structure |
CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
CH648754A5 (en) | 1979-08-16 | 1985-04-15 | Ciba Geigy Ag | Pharmaceutical slow release tablet |
US4353887A (en) | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
US4457933A (en) | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
JPS56169622A (en) | 1980-06-03 | 1981-12-26 | Kissei Pharmaceut Co Ltd | Method of making solid preparation from oily substance |
DE3024416C2 (de) | 1980-06-28 | 1982-04-15 | Gödecke AG, 1000 Berlin | Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung |
US4473640A (en) | 1982-06-03 | 1984-09-25 | Combie Joan D | Detection of morphine and its analogues using enzymatic hydrolysis |
US4462941A (en) | 1982-06-10 | 1984-07-31 | The Regents Of The University Of California | Dynorphin amide analogs |
US4427778A (en) | 1982-06-29 | 1984-01-24 | Biochem Technology, Inc. | Enzymatic preparation of particulate cellulose for tablet making |
US4485211A (en) | 1982-09-15 | 1984-11-27 | The B. F. Goodrich Company | Poly(glycidyl ether)block copolymers and process for their preparation |
US4427681A (en) | 1982-09-16 | 1984-01-24 | Richardson-Vicks, Inc. | Thixotropic compositions easily convertible to pourable liquids |
US4529583A (en) | 1983-03-07 | 1985-07-16 | Clear Lake Development Group | Composition and method of immobilizing emetics and method of treating human beings with emetics |
US4603143A (en) | 1983-05-02 | 1986-07-29 | Basf Corporation | Free-flowing, high density, fat soluble vitamin powders with improved stability |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US5082668A (en) | 1983-05-11 | 1992-01-21 | Alza Corporation | Controlled-release system with constant pushing source |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4599342A (en) | 1984-01-16 | 1986-07-08 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
US4629621A (en) | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
AU592065B2 (en) | 1984-10-09 | 1990-01-04 | Dow Chemical Company, The | Sustained release dosage form based on highly plasticized cellulose ether gels |
GB8507779D0 (en) | 1985-03-26 | 1985-05-01 | Fujisawa Pharmaceutical Co | Drug carrier |
ZA864681B (en) | 1985-06-24 | 1987-02-25 | Ici Australia Ltd | Ingestible capsules |
DE3665262D1 (en) | 1985-06-28 | 1989-10-05 | Carrington Lab Inc | Processes for preparation of aloe products, products produced thereby and compositions thereof |
US4992279A (en) | 1985-07-03 | 1991-02-12 | Kraft General Foods, Inc. | Sweetness inhibitor |
US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
DE3689650T2 (de) | 1985-12-17 | 1994-05-26 | United States Surgical Corp | Bioresorbierbare Polymere von hohem Molekulargewicht und Implantate davon. |
US5229164A (en) | 1985-12-19 | 1993-07-20 | Capsoid Pharma Gmbh | Process for producing individually dosed administration forms |
US4711894A (en) | 1986-01-16 | 1987-12-08 | Henkel Corporation | Stabilized tocopherol in dry, particulate, free-flowing form |
US5198226A (en) | 1986-01-30 | 1993-03-30 | Syntex (U.S.A.) Inc. | Long acting nicardipine hydrochloride formulation |
US4940556A (en) | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
US4764378A (en) | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
AU7077287A (en) | 1986-03-31 | 1987-10-08 | Union Carbide Corporation | Alkylene oxide polymerisation catalyst |
DE3612211A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Kontinuierliches verfahren zum tablettieren |
US4667013A (en) | 1986-05-02 | 1987-05-19 | Union Carbide Corporation | Process for alkylene oxide polymerization |
USRE33093E (en) | 1986-06-16 | 1989-10-17 | Johnson & Johnson Consumer Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
US4713243A (en) | 1986-06-16 | 1987-12-15 | Johnson & Johnson Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
USRE34990E (en) | 1986-08-07 | 1995-07-04 | Ciba-Geigy Corporation | Oral therapeutic system having systemic action |
CA1335748C (en) | 1986-09-25 | 1995-05-30 | Jeffrey Lawrence Finnan | Crosslinked gelatins |
US5227157A (en) | 1986-10-14 | 1993-07-13 | Board Of Regents, The University Of Texas System | Delivery of therapeutic agents |
DE3778006D1 (de) | 1986-11-10 | 1992-05-07 | Biopure Corp | Hochreines, halbsynthetisches blutsurrogat. |
US4892889A (en) | 1986-11-18 | 1990-01-09 | Basf Corporation | Process for making a spray-dried, directly-compressible vitamin powder comprising unhydrolyzed gelatin |
JPH0831303B2 (ja) | 1986-12-01 | 1996-03-27 | オムロン株式会社 | チツプ型ヒユ−ズ |
EP0277092B1 (de) | 1987-01-14 | 1992-01-29 | Ciba-Geigy Ag | Therapeutisches System für schwerlösliche Wirkstoffe |
US4892778A (en) | 1987-05-27 | 1990-01-09 | Alza Corporation | Juxtaposed laminated arrangement |
US5051261A (en) | 1987-11-24 | 1991-09-24 | Fmc Corporation | Method for preparing a solid sustained release form of a functionally active composition |
DE3877971T2 (de) | 1987-12-17 | 1993-06-09 | Upjohn Co | Dreifach gekerbte arzneimitteltablette. |
DE3812567A1 (de) | 1988-04-15 | 1989-10-26 | Basf Ag | Verfahren zur herstellung pharmazeutischer mischungen |
US4954346A (en) | 1988-06-08 | 1990-09-04 | Ciba-Geigy Corporation | Orally administrable nifedipine solution in a solid light resistant dosage form |
US4960814A (en) | 1988-06-13 | 1990-10-02 | Eastman Kodak Company | Water-dispersible polymeric compositions |
US5350741A (en) | 1988-07-30 | 1994-09-27 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
JPH0249719A (ja) | 1988-08-11 | 1990-02-20 | Dai Ichi Kogyo Seiyaku Co Ltd | 易水分散・可溶性能を有する油溶性ビタミン粉末 |
GB8820327D0 (en) | 1988-08-26 | 1988-09-28 | May & Baker Ltd | New compositions of matter |
DE3830353A1 (de) | 1988-09-07 | 1990-03-15 | Basf Ag | Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen |
US5004601A (en) | 1988-10-14 | 1991-04-02 | Zetachron, Inc. | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith |
US5139790A (en) | 1988-10-14 | 1992-08-18 | Zetachron, Inc. | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith |
US4957668A (en) | 1988-12-07 | 1990-09-18 | General Motors Corporation | Ultrasonic compacting and bonding particles |
US5190760A (en) | 1989-07-08 | 1993-03-02 | Coopers Animal Health Limited | Solid pharmaceutical composition |
US5169645A (en) | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
US5200197A (en) | 1989-11-16 | 1993-04-06 | Alza Corporation | Contraceptive pill |
GB8926612D0 (en) | 1989-11-24 | 1990-01-17 | Erba Farmitalia | Pharmaceutical compositions |
EP0449775A3 (en) | 1990-03-29 | 1992-09-02 | Ciba-Geigy Ag | Polyether-polyester block copolymers and their use as dispersing agents |
SU1759445A1 (ru) | 1990-06-15 | 1992-09-07 | Ленинградский Технологический Институт Им.Ленсовета | Способ получени капсулированных гидрофобных веществ |
FR2664851B1 (fr) | 1990-07-20 | 1992-10-16 | Oreal | Procede de compactage d'un melange pulverulent permettant d'obtenir un produit compact absorbant ou partiellement delitable et produit obtenu par ce procede. |
EP0477135A1 (en) | 1990-09-07 | 1992-03-25 | Warner-Lambert Company | Chewable spheroidal coated microcapsules and methods for preparing same |
US5126151A (en) | 1991-01-24 | 1992-06-30 | Warner-Lambert Company | Encapsulation matrix |
US5273758A (en) | 1991-03-18 | 1993-12-28 | Sandoz Ltd. | Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms |
US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
JP3073054B2 (ja) | 1991-07-11 | 2000-08-07 | 住友精化株式会社 | アルキレンオキシド重合体の製造方法 |
CA2116563C (en) | 1991-08-30 | 2001-07-03 | Yoji Ito | Dry gel pharmaceutical composition |
WO1993006723A1 (en) | 1991-10-04 | 1993-04-15 | Olin Corporation | Fungicide tablet |
EP0664118B1 (en) | 1991-10-04 | 1999-08-25 | Yoshitomi Pharmaceutical Industries, Ltd. | Sustained-release tablet |
DE4138513A1 (de) | 1991-11-23 | 1993-05-27 | Basf Ag | Feste pharmazeutische retardform |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
DE69212497T2 (de) | 1991-12-05 | 1996-12-12 | Mallinckrodt Veterinary, Inc., Mundelein, Ill. | Glasartige kohlenhydratenmatrize zur verabreichung von heilmitteln mit verzögerter wirkstoffabgabe |
US5200194A (en) | 1991-12-18 | 1993-04-06 | Alza Corporation | Oral osmotic device |
WO1993011749A1 (en) | 1991-12-18 | 1993-06-24 | Warner-Lambert Company | A process for the preparation of a solid dispersion |
US5225417A (en) | 1992-01-21 | 1993-07-06 | G. D. Searle & Co. | Opioid agonist compounds |
IL105553A (en) | 1992-05-06 | 1998-01-04 | Janssen Pharmaceutica Inc | Solid dosage forms consisting of a porous network of matrix that releases a substance that dissipates rapidly in water |
US5792474A (en) | 1992-05-22 | 1998-08-11 | Goedecke Aktiengesellschaft | Process for the production of retarded pharmaceutical compositions |
GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
DE4227385A1 (de) | 1992-08-19 | 1994-02-24 | Kali Chemie Pharma Gmbh | Pankreatinmikropellets |
DE4229085C2 (de) | 1992-09-01 | 1996-07-11 | Boehringer Mannheim Gmbh | Längliche, teilbare Tablette |
CZ291495B6 (cs) | 1992-09-18 | 2003-03-12 | Yamanouchi Pharmaceutical Co., Ltd. | Hydrogelotvorný farmaceutický přípravek s prodlouženým uvolňováním |
US5472943A (en) | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
FI101039B (fi) | 1992-10-09 | 1998-04-15 | Eeva Kristoffersson | Menetelmä lääkepellettien valmistamiseksi |
AU679937B2 (en) | 1992-11-18 | 1997-07-17 | Johnson & Johnson Consumer Products, Inc. | Extrudable compositions for topical or transdermal drug delivery |
ES2138070T3 (es) | 1992-12-23 | 2000-01-01 | Saitec Srl | Proceso para la preparacion de formas farmaceuticas de liberacion controlada y las formas obtenidas de esta manera. |
GB2273874A (en) | 1992-12-31 | 1994-07-06 | Pertti Olavi Toermaelae | Preparation of pharmaceuticals in a polymer matrix |
US6071970A (en) | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
US5914132A (en) | 1993-02-26 | 1999-06-22 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
DE4309528C2 (de) | 1993-03-24 | 1998-05-20 | Doxa Gmbh | Folie oder Folienschlauch aus Casein, Verfahren zu deren Herstellung und deren Verwendung |
IL119660A (en) | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
IL109944A (en) | 1993-07-01 | 1998-12-06 | Euro Celtique Sa | Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms |
DE4329794C2 (de) | 1993-09-03 | 1997-09-18 | Gruenenthal Gmbh | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung |
EP1442745A1 (en) | 1993-10-07 | 2004-08-04 | Euro-Celtique | Orally administrable opioid formulations having extended duration of effect |
ATE212224T1 (de) | 1993-11-23 | 2002-02-15 | Euro Celtique Sa | Verfahren zur herstellung einer arzneizusammensetzung mit verzögerter wirkstoffabgabe |
KR100354702B1 (ko) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
WO1995017174A1 (en) | 1993-12-20 | 1995-06-29 | The Procter & Gamble Company | Process for making laxatives containing dioctyl sulfosuccinate |
IL112106A0 (en) | 1993-12-22 | 1995-03-15 | Ergo Science Inc | Accelerated release composition containing bromocriptine |
GB9401894D0 (en) | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
CA2182282C (en) | 1994-02-16 | 2006-04-18 | Jacqueline E. Briskin | Process for preparing fine particle pharmaceutical formulations |
SE9503924D0 (sv) | 1995-08-18 | 1995-11-07 | Astra Ab | Novel opioid peptides |
US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
DE4413350A1 (de) | 1994-04-18 | 1995-10-19 | Basf Ag | Retard-Matrixpellets und Verfahren zu ihrer Herstellung |
RO114740B1 (ro) | 1994-05-06 | 1999-07-30 | Pfizer | Compozitie cu eliberare controlata, procedeu de obtinere a acesteia si metoda de tratament |
DE19509807A1 (de) | 1995-03-21 | 1996-09-26 | Basf Ag | Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen |
AT403988B (de) | 1994-05-18 | 1998-07-27 | Lannacher Heilmittel | Festes orales retardpräparat |
US5460826A (en) | 1994-06-27 | 1995-10-24 | Alza Corporation | Morphine therapy |
DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
IT1274879B (it) | 1994-08-03 | 1997-07-25 | Saitec Srl | Apparecchio e metodo per preparare forme farmaceutiche solide a rilascio controllato del principio attivo. |
JP3285452B2 (ja) | 1994-08-11 | 2002-05-27 | サンスター株式会社 | 歯磨組成物 |
US5837790A (en) | 1994-10-24 | 1998-11-17 | Amcol International Corporation | Precipitation polymerization process for producing an oil adsorbent polymer capable of entrapping solid particles and liquids and the product thereof |
AUPM897594A0 (en) | 1994-10-25 | 1994-11-17 | Daratech Pty Ltd | Controlled release container |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
DE4446470A1 (de) | 1994-12-23 | 1996-06-27 | Basf Ag | Verfahren zur Herstellung von teilbaren Tabletten |
DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
US6348469B1 (en) | 1995-04-14 | 2002-02-19 | Pharma Pass Llc | Solid compositions containing glipizide and polyethylene oxide |
US6117453A (en) | 1995-04-14 | 2000-09-12 | Pharma Pass | Solid compositions containing polyethylene oxide and an active ingredient |
US5900425A (en) | 1995-05-02 | 1999-05-04 | Bayer Aktiengesellschaft | Pharmaceutical preparations having controlled release of active compound and processes for their preparation |
DE19522899C1 (de) | 1995-06-23 | 1996-12-19 | Hexal Pharmaforschung Gmbh | Verfahren zum kontinuierlichen Ersintern eines Granulats |
US5759583A (en) | 1995-08-30 | 1998-06-02 | Syntex (U.S.A.) Inc. | Sustained release poly (lactic/glycolic) matrices |
US6063405A (en) | 1995-09-29 | 2000-05-16 | L.A.M. Pharmaceuticals, Llc | Sustained release delivery system |
US5811126A (en) | 1995-10-02 | 1998-09-22 | Euro-Celtique, S.A. | Controlled release matrix for pharmaceuticals |
DE19539361A1 (de) | 1995-10-23 | 1997-04-24 | Basf Ag | Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung |
US6355656B1 (en) | 1995-12-04 | 2002-03-12 | Celgene Corporation | Phenidate drug formulations having diminished abuse potential |
US5908850A (en) | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
DE19547766A1 (de) | 1995-12-20 | 1997-06-26 | Gruenenthal Gmbh | 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-verbindungen als pharmazeutische Wirkstoffe |
EP0914097B1 (en) | 1996-03-12 | 2002-01-16 | Alza Corporation | Composition and dosage form comprising opioid antagonist |
US6461644B1 (en) | 1996-03-25 | 2002-10-08 | Richard R. Jackson | Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods |
KR19990087076A (ko) | 1996-04-05 | 1999-12-15 | 다께다 구니오 | 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는 약제학적 배합물 |
US6096339A (en) | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
US20020114838A1 (en) | 1996-04-05 | 2002-08-22 | Ayer Atul D. | Uniform drug delivery therapy |
WO1997046224A1 (en) | 1996-06-06 | 1997-12-11 | Bifodan A/S | Enteric coating, comprising alginic acid, for an oral preparation |
WO1997049384A1 (en) | 1996-06-26 | 1997-12-31 | Board Of Regents, The University Of Texas System | Hot-melt extrudable pharmaceutical formulation |
CA2231195C (en) | 1996-07-08 | 2003-01-21 | Edward Mendell Co., Inc. | Sustained release matrix for high-dose insoluble drugs |
DE19629753A1 (de) | 1996-07-23 | 1998-01-29 | Basf Ag | Verfahren zur Herstellung von festen Arzneiformen |
NL1003684C2 (nl) | 1996-07-25 | 1998-01-28 | Weterings B V H | Inrichting voor het afgeven van een vloeistof. |
DE19630236A1 (de) | 1996-07-26 | 1998-01-29 | Wolff Walsrode Ag | Biaxial gereckte, biologisch abbaubare und kompostierbare Wursthülle |
BE1010353A5 (fr) | 1996-08-14 | 1998-06-02 | Boss Pharmaceuticals Ag | Procede pour la fabrication de produits pharmaceutiques, dispositif pour un tel procede et produits pharmaceutiques ainsi obtenus. |
EP0947559B1 (en) | 1996-11-05 | 2004-10-27 | NOVAMONT S.p.A. | Biodegradable polymeric compositions comprising starch and a thermoplastic polymer |
US5991799A (en) | 1996-12-20 | 1999-11-23 | Liberate Technologies | Information retrieval system using an internet multiplexer to focus user selection |
DE19705538C1 (de) | 1997-02-14 | 1998-08-27 | Goedecke Ag | Verfahren zur Trennung von Wirkstoffen in festen pharmazeutischen Zubereitungen |
US5948787A (en) | 1997-02-28 | 1999-09-07 | Alza Corporation | Compositions containing opiate analgesics |
DE19710213A1 (de) | 1997-03-12 | 1998-09-17 | Basf Ag | Verfahren zur Herstellung von festen Kombinationsarzneiformen |
DE19710008A1 (de) | 1997-03-12 | 1998-09-17 | Basf Ag | Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung |
DE19710009A1 (de) | 1997-03-12 | 1998-09-24 | Knoll Ag | Mehrphasige wirkstoffhaltige Zubereitungsformen |
US6139770A (en) | 1997-05-16 | 2000-10-31 | Chevron Chemical Company Llc | Photoinitiators and oxygen scavenging compositions |
DE19721467A1 (de) | 1997-05-22 | 1998-11-26 | Basf Ag | Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
PT998271E (pt) | 1997-06-06 | 2005-10-31 | Depomed Inc | Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis |
CA2270975C (en) | 1997-07-02 | 2003-04-01 | Euro-Celtique, S.A. | Stabilized sustained release tramadol formulations |
IE970588A1 (en) | 1997-08-01 | 2000-08-23 | Elan Corp Plc | Controlled release pharmaceutical compositions containing tiagabine |
KR100588097B1 (ko) | 1997-09-10 | 2006-06-09 | 알라이드시그날 인코포레이티드 | 수성공정에 의한 지르코니아계 구조재료의 사출주조법 |
US6009390A (en) | 1997-09-11 | 1999-12-28 | Lucent Technologies Inc. | Technique for selective use of Gaussian kernels and mixture component weights of tied-mixture hidden Markov models for speech recognition |
CA2310847C (en) | 1997-11-28 | 2007-03-13 | Knoll Aktiengesellschaft | Method for producing solvent-free non-crystalline biologically active substances |
DE19753534A1 (de) | 1997-12-03 | 1999-06-10 | Bayer Ag | Schnell kristallisierende, biologisch abbaubare Polyesteramide |
CA2312479A1 (en) | 1997-12-03 | 1999-06-10 | Bayer Aktiengesellschaft | Polyether ester amides |
TR200001828T2 (tr) | 1997-12-22 | 2000-11-21 | Euro-Celtique, S.A. | Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem. |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
DE19800698A1 (de) | 1998-01-10 | 1999-07-15 | Bayer Ag | Biologisch abbaubare Polyesteramide mit blockartig aufgebauten Polyester- und Polyamid-Segmenten |
DE19800689C1 (de) | 1998-01-10 | 1999-07-15 | Deloro Stellite Gmbh | Formkörper aus einem verschleißfesten Werkstoff |
US6251430B1 (en) | 1998-02-04 | 2001-06-26 | Guohua Zhang | Water insoluble polymer based sustained release formulation |
CN1296516A (zh) | 1998-02-06 | 2001-05-23 | 联合碳化化学品及塑料技术公司 | 烯化氧聚合物组合物 |
DE69918233T2 (de) | 1998-03-05 | 2005-02-24 | Mitsui Chemicals, Inc. | Polymilchsäure zusammensetzung und daraus hergestellter film |
US6245357B1 (en) | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
US6090411A (en) | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
US6110500A (en) | 1998-03-25 | 2000-08-29 | Temple University | Coated tablet with long term parabolic and zero-order release kinetics |
EP1070346A1 (en) | 1998-04-02 | 2001-01-24 | Applied Materials, Inc. | Method for etching low k dielectrics |
EP1067910B1 (en) | 1998-04-03 | 2004-05-26 | Egalet A/S | Controlled release composition |
US5962488A (en) | 1998-04-08 | 1999-10-05 | Roberts Laboratories, Inc. | Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives |
DE19822979A1 (de) | 1998-05-25 | 1999-12-02 | Kalle Nalo Gmbh & Co Kg | Folie mit Stärke oder Stärkederivaten und Polyesterurethanen sowie Verfahren zu ihrer Herstellung |
US6333087B1 (en) | 1998-08-27 | 2001-12-25 | Chevron Chemical Company Llc | Oxygen scavenging packaging |
DE19841244A1 (de) | 1998-09-09 | 2000-03-16 | Knoll Ag | Verfahren und Vorrichtung zum Herstellen von Tabletten |
GT199900148A (es) | 1998-09-10 | 2001-02-28 | Desnaturalizantes para las sales aminas simpaticomimeticas. | |
US6268177B1 (en) | 1998-09-22 | 2001-07-31 | Smithkline Beecham Corporation | Isolated nucleic acid encoding nucleotide pyrophosphorylase |
WO2000023073A1 (en) | 1998-10-20 | 2000-04-27 | Korea Institute Of Science And Technology | Bioflavonoids as plasma high density lipoprotein level increasing agent |
US20010055613A1 (en) | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
US20060240105A1 (en) | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
ES2141688B1 (es) | 1998-11-06 | 2001-02-01 | Vita Invest Sa | Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos. |
DE19855440A1 (de) | 1998-12-01 | 2000-06-08 | Basf Ag | Verfahren zum Herstellen fester Darreichungsformen mittels Schmelzextrusion |
EP1005863A1 (en) | 1998-12-04 | 2000-06-07 | Synthelabo | Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof |
DE19856147A1 (de) | 1998-12-04 | 2000-06-08 | Knoll Ag | Teilbare feste Dosierungsformen und Verfahren zu ihrer Herstellung |
US6238697B1 (en) | 1998-12-21 | 2001-05-29 | Pharmalogix, Inc. | Methods and formulations for making bupropion hydrochloride tablets using direct compression |
AU3469100A (en) | 1999-01-05 | 2000-07-24 | Copley Pharmaceutical Inc. | Sustained release formulation with reduced moisture sensitivity |
WO2000045830A1 (fr) | 1999-02-04 | 2000-08-10 | Nichimo Co., Ltd. | Substances permettant d'eviter la survenue de l'arteriosclerose, substances immunostimulantes, vertebres nourris a l'aide ces substances et oeufs de ces vertebres |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6375963B1 (en) | 1999-06-16 | 2002-04-23 | Michael A. Repka | Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof |
US6384020B1 (en) | 1999-07-14 | 2002-05-07 | Shire Laboratories, Inc. | Rapid immediate release oral dosage form |
JP2003522127A (ja) | 1999-07-29 | 2003-07-22 | ロクセニ ラボラトリーズ インコーポレイテッド | オピオイド徐放性製剤 |
US20030118641A1 (en) | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
WO2001010466A1 (fr) | 1999-08-04 | 2001-02-15 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicinales stables pour administration orale |
US6562375B1 (en) | 1999-08-04 | 2003-05-13 | Yamanouchi Pharmaceuticals, Co., Ltd. | Stable pharmaceutical composition for oral use |
KR100345214B1 (ko) | 1999-08-17 | 2002-07-25 | 이강춘 | 생체적합성 고분자가 수식된 펩타이드의 비점막 전달 |
DE19940944B4 (de) | 1999-08-31 | 2006-10-12 | Grünenthal GmbH | Retardierte, orale, pharmazeutische Darreichungsformen |
DE19940740A1 (de) | 1999-08-31 | 2001-03-01 | Gruenenthal Gmbh | Pharmazeutische Salze |
JP2003508430A (ja) | 1999-08-31 | 2003-03-04 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | トラマドールサッカリナートを含有する徐放性投薬形 |
DE19960494A1 (de) | 1999-12-15 | 2001-06-21 | Knoll Ag | Vorrichtung und Verfahren zum Herstellen von festen wirkstoffhaltigen Formen |
ES2160534B1 (es) | 1999-12-30 | 2002-04-16 | Vita Invest Sa | Nuevos esteres derivados de (rr,ss)-2-hidroxibenzoato de 3-(2-dimetilaminometil-1-hidroxiciclohexil) fenilo. |
US6680070B1 (en) | 2000-01-18 | 2004-01-20 | Albemarle Corporation | Particulate blends and compacted products formed therefrom, and the preparation thereof |
NZ520554A (en) | 2000-02-08 | 2005-08-26 | Euro Celtique S | Tamper-resistant oral opioid agonist formulations |
US20020015730A1 (en) | 2000-03-09 | 2002-02-07 | Torsten Hoffmann | Pharmaceutical formulations and method for making |
DE10015479A1 (de) | 2000-03-29 | 2001-10-11 | Basf Ag | Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität |
US8012504B2 (en) | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US6572887B2 (en) | 2000-05-01 | 2003-06-03 | National Starch And Chemical Investment Holding Corporation | Polysaccharide material for direct compression |
US6419954B1 (en) | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
BR0111125A (pt) | 2000-05-23 | 2004-12-28 | Cenes Pharmaceuticals Inc | Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos |
DE10029201A1 (de) | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
US6607748B1 (en) | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
DE10036400A1 (de) | 2000-07-26 | 2002-06-06 | Mitsubishi Polyester Film Gmbh | Weiße, biaxial orientierte Polyesterfolie |
GB2381456B (en) | 2000-09-27 | 2004-08-04 | Danisco | An anhydrofructose derived antimicrobial agent |
AU2001294902A1 (en) | 2000-09-28 | 2002-04-08 | The Dow Chemical Company | Polymer composite structures useful for controlled release systems |
DE10048773B4 (de) | 2000-09-29 | 2008-04-03 | Hepro Gmbh | Vorrichtung und Verfahren zum Schälen von Schälgut |
GB0026137D0 (en) | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
US6344215B1 (en) | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
JP2004512354A (ja) | 2000-10-30 | 2004-04-22 | ユーロ−セルティーク,エス.エイ. | ヒドロコドン放出制御製剤 |
WO2002035991A2 (en) | 2000-10-30 | 2002-05-10 | The Board Of Regents, The University Of Texas System | Spherical particles produced by a hot-melt extrusion/spheronization process |
DE10109763A1 (de) | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
JP2002265592A (ja) | 2001-03-07 | 2002-09-18 | Sumitomo Seika Chem Co Ltd | アルキレンオキシド重合体の製造方法 |
WO2002071860A1 (en) | 2001-03-13 | 2002-09-19 | L.A. Dreyfus Co. | Gum base and gum manufacturing using particulated gum base ingredients |
JP3967554B2 (ja) | 2001-03-15 | 2007-08-29 | 株式会社ポッカコーポレーション | フラボノイド化合物及びその製造方法 |
EP1241110A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Dispensing unit for oxygen-sensitive drugs |
US20020132395A1 (en) | 2001-03-16 | 2002-09-19 | International Business Machines Corporation | Body contact in SOI devices by electrically weakening the oxide under the body |
AU2002248792B2 (en) | 2001-04-18 | 2006-09-21 | Nostrum Pharmaceuticals Inc. | A novel coating for a sustained release pharmaceutical composition |
US20020187192A1 (en) | 2001-04-30 | 2002-12-12 | Yatindra Joshi | Pharmaceutical composition which reduces or eliminates drug abuse potential |
WO2002088217A1 (en) | 2001-05-01 | 2002-11-07 | Union Carbide Chemicals & Plastics Technology Corporation | Poly(alkylene oxides) having reduced amounts of formic compounds |
UA81224C2 (uk) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
WO2002090316A1 (en) | 2001-05-08 | 2002-11-14 | The Johns Hopkins University | Method of inhibiting methamphetamine synthesis |
CN1525851A (zh) | 2001-05-11 | 2004-09-01 | ������ҩ������˾ | 抗滥用阿片样物质控释剂型 |
US6623754B2 (en) | 2001-05-21 | 2003-09-23 | Noveon Ip Holdings Corp. | Dosage form of N-acetyl cysteine |
WO2002094172A2 (en) | 2001-05-22 | 2002-11-28 | Euro-Celtique | Compartmentalized dosage form |
US20030064122A1 (en) | 2001-05-23 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse resistant pharmaceutical composition containing capsaicin |
WO2003002100A1 (en) | 2001-06-26 | 2003-01-09 | Farrell John J | Tamper-proof narcotic delivery system |
US20030008409A1 (en) | 2001-07-03 | 2003-01-09 | Spearman Steven R. | Method and apparatus for determining sunlight exposure |
CN1268338C (zh) | 2001-07-06 | 2006-08-09 | 恩德制药公司 | 用作止痛剂的6-羟基羟吗啡酮的口服给药 |
US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
EP1404332A1 (en) | 2001-07-06 | 2004-04-07 | Penwest Pharmaceuticals Company | Methods of making sustained release formulations of oxymorphone related applications |
JP2003020517A (ja) | 2001-07-10 | 2003-01-24 | Calp Corp | 複合繊維用樹脂組成物 |
DK1416842T3 (da) | 2001-07-18 | 2009-03-16 | Euro Celtique Sa | Farmaceutiske kombinationer af oxycodon og naloxon |
US6883976B2 (en) | 2001-07-30 | 2005-04-26 | Seikoh Giken Co., Ltd. | Optical fiber ferrule assembly and optical module and optical connector using the same |
US7144587B2 (en) | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
BR0212019A (pt) | 2001-08-06 | 2005-08-09 | Euro Celtique Sa | Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
KR20040025741A (ko) | 2001-08-06 | 2004-03-25 | 유로-셀티크 소시에떼 아노뉨 | 오피오이드 남용을 방지하기 위한 조성물 및 방법 |
US7332182B2 (en) | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US20030157168A1 (en) | 2001-08-06 | 2003-08-21 | Christopher Breder | Sequestered antagonist formulations |
US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US7157103B2 (en) | 2001-08-06 | 2007-01-02 | Euro-Celtique S.A. | Pharmaceutical formulation containing irritant |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
AU2002321879A1 (en) | 2001-08-06 | 2003-03-03 | Thomas Gruber | Pharmaceutical formulation containing dye |
US20030049272A1 (en) | 2001-08-30 | 2003-03-13 | Yatindra Joshi | Pharmaceutical composition which produces irritation |
US6691698B2 (en) | 2001-09-14 | 2004-02-17 | Fmc Technologies Inc. | Cooking oven having curved heat exchanger |
US20030059467A1 (en) | 2001-09-14 | 2003-03-27 | Pawan Seth | Pharmaceutical composition comprising doxasozin |
US20030059397A1 (en) | 2001-09-17 | 2003-03-27 | Lyn Hughes | Dosage forms |
US20030068276A1 (en) | 2001-09-17 | 2003-04-10 | Lyn Hughes | Dosage forms |
US20030092724A1 (en) | 2001-09-18 | 2003-05-15 | Huaihung Kao | Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic |
WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
ATE381924T1 (de) | 2001-09-21 | 2008-01-15 | Egalet As | Feste dispersionen mit kontrollierter freisetzung von carvedilol |
EP1429735A2 (de) | 2001-09-26 | 2004-06-23 | Klaus-Jürgen Steffens | Verfahren und vorrichtung zur herstellung von granulaten umfassend mindestens einen pharmazeutischen wirkstoff |
CA2459976A1 (en) | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
CN1596100A (zh) | 2001-09-28 | 2005-03-16 | 麦克内尔-Ppc股份有限公司 | 可食用组合物及含可食用外壳的制剂 |
US6837696B2 (en) | 2001-09-28 | 2005-01-04 | Mcneil-Ppc, Inc. | Apparatus for manufacturing dosage forms |
ES2261741T3 (es) | 2001-10-09 | 2006-11-16 | THE PROCTER & GAMBLE COMPANY | Composiciones acuosas para tratar una superficie. |
US6592901B2 (en) | 2001-10-15 | 2003-07-15 | Hercules Incorporated | Highly compressible ethylcellulose for tableting |
JP2003125706A (ja) | 2001-10-23 | 2003-05-07 | Lion Corp | 口中清涼製剤 |
PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US20030152622A1 (en) | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US20030104052A1 (en) | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
JP4551089B2 (ja) | 2001-10-29 | 2010-09-22 | マサチューセッツ インスティテュート オブ テクノロジー | 三次元印刷により製造されたゼロ次放出プロフィール投薬形態のような徐放投薬形態を製造するためのシステム |
EP1450824A4 (en) | 2001-11-02 | 2005-09-28 | Elan Corp Plc | PHARMACEUTICAL COMPOSITION |
US20040126428A1 (en) | 2001-11-02 | 2004-07-01 | Lyn Hughes | Pharmaceutical formulation including a resinate and an aversive agent |
WO2003049689A2 (en) | 2001-12-06 | 2003-06-19 | Nutraceutix, Inc. | Isoflavone composition for oral delivery |
FR2833838B1 (fr) | 2001-12-21 | 2005-09-16 | Ellipse Pharmaceuticals | Procede de fabrication d'un comprime incluant un analgesique de type morphinique et comprime obtenu |
AUPS044502A0 (en) | 2002-02-11 | 2002-03-07 | Commonwealth Scientific And Industrial Research Organisation | Novel catalysts and processes for their preparation |
US20040033253A1 (en) | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
US20030158265A1 (en) | 2002-02-20 | 2003-08-21 | Ramachandran Radhakrishnan | Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same |
US20030190343A1 (en) | 2002-03-05 | 2003-10-09 | Pfizer Inc. | Palatable pharmaceutical compositions for companion animals |
US6572889B1 (en) | 2002-03-07 | 2003-06-03 | Noveon Ip Holdings Corp. | Controlled release solid dosage carbamazepine formulations |
US6753009B2 (en) | 2002-03-13 | 2004-06-22 | Mcneil-Ppc, Inc. | Soft tablet containing high molecular weight polyethylene oxide |
KR20040098050A (ko) | 2002-04-05 | 2004-11-18 | 유로-셀띠끄 소시에떼 아노님 | 옥시코돈 및 날록손을 포함하는 약제학적 제제 |
DE10217232B4 (de) | 2002-04-18 | 2004-08-19 | Ticona Gmbh | Verfahren zur Herstellung gefüllter Granulate aus Polyethylenen hohen bzw. ultrahohen Molekulargewichts |
AU2003234159A1 (en) | 2002-04-22 | 2003-11-03 | Purdue Research Foundation | Hydrogels having enhanced elasticity and mechanical strength properties |
RU2004134594A (ru) | 2002-04-29 | 2005-06-27 | Алза Корпорейшн (Us) | Способы и лекарственные формы для контролируемой доставки оксикодона |
US20050106249A1 (en) | 2002-04-29 | 2005-05-19 | Stephen Hwang | Once-a-day, oral, controlled-release, oxycodone dosage forms |
AU2003234395B2 (en) | 2002-05-13 | 2008-01-24 | Endo Pharmaceuticals Inc. | Abuse-resistant opioid solid dosage form |
IL165361A0 (en) | 2002-05-31 | 2006-01-15 | Alza Corp | Dosage forms and compositions for osmotic deliveryof variable dosages of oxycodone |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE10250083A1 (de) | 2002-06-17 | 2003-12-24 | Gruenenthal Gmbh | Gegen Missbrauch gesicherte Darreichungsform |
WO2004004693A1 (en) | 2002-07-05 | 2004-01-15 | Collgegium Pharmaceutical | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
US20040011806A1 (en) | 2002-07-17 | 2004-01-22 | Luciano Packaging Technologies, Inc. | Tablet filler device with star wheel |
AR040680A1 (es) | 2002-07-25 | 2005-04-13 | Pharmacia Corp | Composicion de tabletas de liberacion sostenida |
US7388068B2 (en) | 2002-08-21 | 2008-06-17 | Clariant Produkte (Deutschland) Gmbh | Copolymers made of alkylene oxides and glycidyl ethers and use thereof as polymerizable emulsifiers |
EP1539112A1 (en) | 2002-08-21 | 2005-06-15 | Phoqus Pharmaceuticals Limited | Use of an aqueous solution of citric acid and a water-soluble sugar like lactitol as granulation liquid in the manufacture of tablets |
US20040052844A1 (en) | 2002-09-16 | 2004-03-18 | Fang-Hsiung Hsiao | Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins |
US20040077677A1 (en) | 2002-09-17 | 2004-04-22 | Wyeth | Oral formulations |
NZ538859A (en) | 2002-09-20 | 2006-12-22 | Fmc Corp | Cosmetic sunscreen composition containing microcrystalline cellulose |
WO2004026308A1 (fr) | 2002-09-21 | 2004-04-01 | Shuyi Zhang | Compose d'acetamidophenol et de tramadol a liberation prolongee |
EP1551402A4 (en) | 2002-09-23 | 2009-05-27 | Verion Inc | PHARMACEUTICAL COMPOSITIONS NOT INDUCING ABUSE |
DE10250084A1 (de) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE10250088A1 (de) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US20050186139A1 (en) | 2002-10-25 | 2005-08-25 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10250087A1 (de) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US20050191244A1 (en) | 2002-10-25 | 2005-09-01 | Gruenenthal Gmbh | Abuse-resistant pharmaceutical dosage form |
RU2328275C2 (ru) | 2002-10-25 | 2008-07-10 | Лабофарм Инк. | Композиции трамадола пролонгированного высвобождения с 24-часовым действием |
DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
US20040091528A1 (en) | 2002-11-12 | 2004-05-13 | Yamanouchi Pharma Technologies, Inc. | Soluble drug extended release system |
US7018658B2 (en) | 2002-11-14 | 2006-03-28 | Synthon Bv | Pharmaceutical pellets comprising tamsulosin |
US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
US7442387B2 (en) | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
WO2004082620A2 (en) | 2003-03-13 | 2004-09-30 | Controlled Chemicals, Inc. | Oxycodone conjugates with lower the abuse potential and extended duration of action |
DE602004031096D1 (de) | 2003-03-26 | 2011-03-03 | Egalet As | Morphin-system mit kontrollierter freisetzung |
US8298581B2 (en) | 2003-03-26 | 2012-10-30 | Egalet A/S | Matrix compositions for controlled delivery of drug substances |
TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
JP5501553B2 (ja) | 2003-04-21 | 2014-05-21 | ユーロ−セルティーク エス.エイ. | 同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程 |
EA009623B1 (ru) | 2003-04-30 | 2008-02-28 | Пэдью Фарма Л.П. | Устойчивая к манипуляциям дозировочная форма для трансдермального введения |
US8906413B2 (en) | 2003-05-12 | 2014-12-09 | Supernus Pharmaceuticals, Inc. | Drug formulations having reduced abuse potential |
CN1473562A (zh) | 2003-06-27 | 2004-02-11 | 辉 刘 | 儿用口腔速溶、速崩冻干片及其制备方法 |
US20050015730A1 (en) | 2003-07-14 | 2005-01-20 | Srimanth Gunturi | Systems, methods and computer program products for identifying tab order sequence of graphically represented elements |
DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
RU2339365C2 (ru) | 2003-08-06 | 2008-11-27 | Грюненталь Гмбх | Защищенная от применения не по назначению лекарственная форма |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102004020220A1 (de) | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
ES2407143T3 (es) | 2003-08-06 | 2013-06-11 | Grünenthal GmbH | Forma de dosificación protegida contra un posible abuso |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
US20050063214A1 (en) | 2003-09-22 | 2005-03-24 | Daisaburo Takashima | Semiconductor integrated circuit device |
ES2344350T3 (es) | 2003-09-25 | 2010-08-25 | Euro-Celtique S.A. | Combinaciones farmaceuticas de hidrocodona y naltrexona. |
BRPI0414941A (pt) | 2003-09-30 | 2006-11-07 | Alza Corp | dispositivo de distribuição de agente ativo acionado osmoticamente proporcionando um perfil de liberação ascendente |
US20060172006A1 (en) | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
US20060009478A1 (en) | 2003-10-15 | 2006-01-12 | Nadav Friedmann | Methods for the treatment of back pain |
WO2005041968A2 (en) | 2003-10-29 | 2005-05-12 | Alza Corporation | Once-a-day, oral, controlled-release, oxycodone dosage forms |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
EP1689368B1 (en) | 2003-12-04 | 2016-09-28 | Bend Research, Inc | Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions |
DK1691892T3 (da) | 2003-12-09 | 2007-06-25 | Euro Celtique Sa | Anbrudsbestandig, coekstruderet doseringsform, der indeholder et aktivt middel og et modvirkende middel, og fremgangsmåde til fremstilling af samme |
WO2005060942A1 (en) | 2003-12-19 | 2005-07-07 | Aurobindo Pharma Ltd | Extended release pharmaceutical composition of metformin |
DE10360792A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
EP1701706A2 (en) | 2003-12-29 | 2006-09-20 | Alza Corporation | Novel drug compositions and dosage forms |
EP1750717B1 (en) | 2004-02-11 | 2017-07-19 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
GB0403100D0 (en) | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Particulates |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
GB0403098D0 (en) | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
ME02661B (me) | 2004-02-23 | 2017-06-20 | Euro Celtique Sa | Opioidni transdermalni preparat otporan na zloupotrebu |
TWI483944B (zh) | 2004-03-30 | 2015-05-11 | Euro Celtique Sa | 含有小於25ppm14-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝 |
US20050220877A1 (en) | 2004-03-31 | 2005-10-06 | Patel Ashish A | Bilayer tablet comprising an antihistamine and a decongestant |
DE102004019916A1 (de) | 2004-04-21 | 2005-11-17 | Grünenthal GmbH | Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster |
WO2005102286A1 (de) | 2004-04-22 | 2005-11-03 | Grünenthal GmbH | Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreinchungsform |
WO2005105036A1 (en) | 2004-04-28 | 2005-11-10 | Natco Pharma Limited | Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation |
US20050271594A1 (en) | 2004-06-04 | 2005-12-08 | Groenewoud Pieter J | Abuse resistent pharmaceutical composition |
TWI356036B (en) | 2004-06-09 | 2012-01-11 | Smithkline Beecham Corp | Apparatus and method for pharmaceutical production |
PT1612203E (pt) | 2004-06-28 | 2007-08-20 | Gruenenthal Gmbh | ''formas cristalinas de cloridrato de (-) - (1r,2r) - 3 -(3-dimetilamino-l-etil - 2 - metilpropil) fenol'' |
ITMI20041317A1 (it) | 2004-06-30 | 2004-09-30 | Ibsa Inst Biochimique Sa | Formulazioni farmaceutiche per la somministrazione sicura di farmaci utilizzati nel trattamento della tossicodipendenza e procedimento per il loro ottenimento |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
EP1765298B1 (de) | 2004-07-01 | 2012-10-24 | Gruenenthal Gmbh | Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreichungsform unter verwendung eines planetwalzenextruders |
FI1765303T4 (fi) | 2004-07-01 | 2023-01-31 | Väärinkäytöltä suojattu oraalinen tabletti | |
AU2005259478B2 (en) | 2004-07-01 | 2010-07-15 | Gruenenthal Gmbh | Oral dosage form safeguarded against abuse containing (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
DE102004032103A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
BRPI0513608A (pt) | 2004-07-27 | 2008-05-13 | Unilever Nv | composição para o cuidado dos cabelos, processo para a preparação de uma composição para o cuidado dos cabelos e método para o tratamento dos cabelos |
US20060068009A1 (en) | 2004-09-30 | 2006-03-30 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
US20070077297A1 (en) | 2004-09-30 | 2007-04-05 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
US7426948B2 (en) * | 2004-10-08 | 2008-09-23 | Phibrowood, Llc | Milled submicron organic biocides with narrow particle size distribution, and uses thereof |
US20080152595A1 (en) | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060177380A1 (en) | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20070231268A1 (en) | 2004-11-24 | 2007-10-04 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
AU2006209547C1 (en) | 2005-01-26 | 2022-04-07 | Taiho Pharmaceutical Co., Ltd. | Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor |
JP5704789B2 (ja) | 2005-01-28 | 2015-04-22 | ユーロ−セルティーク エス.エイ. | 耐アルコール性剤形 |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
FR2889810A1 (fr) | 2005-05-24 | 2007-02-23 | Flamel Technologies Sa | Forme medicamenteuse orale, microparticulaire, anti-mesurage |
BRPI0606883A2 (pt) | 2005-02-10 | 2009-12-01 | Lifecycle Pharma As | composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única |
US20060194759A1 (en) | 2005-02-25 | 2006-08-31 | Eidelson Stewart G | Topical compositions and methods for treating pain and inflammation |
EP1695700A1 (en) | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
WO2006094672A1 (en) | 2005-03-04 | 2006-09-14 | Euro-Celtique S.A. | Method of reducing alpha, beta unsaturated ketones in opioid compositions |
US20060204575A1 (en) | 2005-03-11 | 2006-09-14 | Hengsheng Feng | Amphetamine formulations |
US7732427B2 (en) | 2005-03-31 | 2010-06-08 | University Of Delaware | Multifunctional and biologically active matrices from multicomponent polymeric solutions |
JP5256425B2 (ja) | 2005-04-08 | 2013-08-07 | リングアル コンセグナ ピーティーワイ エルティーディー | 口腔送達システム |
BRPI0608609A2 (pt) | 2005-05-10 | 2010-01-19 | Novartis Ag | processo de extrusço para preparaÇço de composiÇÕes com compostos terapÊuticos fracamente compressÍveis |
CA2611081C (en) | 2005-06-03 | 2016-05-31 | Egalet A/S | A drug delivery system for delivering active substances dispersed in a dispersion medium |
WO2007005716A2 (en) | 2005-06-30 | 2007-01-11 | Cinergen, Llc | Methods of treatment and compositions for use thereof |
NZ565108A (en) | 2005-07-07 | 2011-10-28 | Farnam Co Inc | Sustained release pharmaceutical compositions for highly water soluble drugs |
DE102005032806A1 (de) | 2005-07-12 | 2007-01-18 | Röhm Gmbh | Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten |
US8858993B2 (en) | 2005-07-25 | 2014-10-14 | Metrics, Inc. | Coated tablet with zero-order or near zero-order release kinetics |
US20070184117A1 (en) | 2005-08-03 | 2007-08-09 | Stephen Gregory | Tocopheryl polyethylene glycol succinate powder and process for preparing same |
US20070048373A1 (en) * | 2005-08-30 | 2007-03-01 | Cima Labs Inc. | Dried milled granulate and methods |
CA2625055C (en) | 2005-10-14 | 2013-12-24 | The Kitasato Institute | Novel dihydropseudoerythromycin derivatives |
US20070092573A1 (en) | 2005-10-24 | 2007-04-26 | Laxminarayan Joshi | Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist |
PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
US8329744B2 (en) | 2005-11-02 | 2012-12-11 | Relmada Therapeutics, Inc. | Methods of preventing the serotonin syndrome and compositions for use thereof |
WO2008134071A1 (en) | 2007-04-26 | 2008-11-06 | Theraquest Biosciences, Inc. | Multimodal abuse resistant extended release formulations |
FR2892937B1 (fr) | 2005-11-10 | 2013-04-05 | Flamel Tech Sa | Forme pharmaceutique orale microparticulaire anti-mesusage |
US8652529B2 (en) | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
DE102005058569B4 (de) | 2005-12-08 | 2010-07-15 | Lts Lohmann Therapie-Systeme Ag | Schaumwafer mit Polyvinylalkohol-Polyethylenglycol-Pfropfcopolymer |
US20090317355A1 (en) | 2006-01-21 | 2009-12-24 | Abbott Gmbh & Co. Kg, | Abuse resistant melt extruded formulation having reduced alcohol interaction |
SG169334A1 (en) | 2006-01-21 | 2011-03-30 | Abbott Gmbh & Co Kg | Dosage form and method for the delivery of drugs of abuse |
US20090022798A1 (en) | 2007-07-20 | 2009-01-22 | Abbott Gmbh & Co. Kg | Formulations of nonopioid and confined opioid analgesics |
US20100172989A1 (en) | 2006-01-21 | 2010-07-08 | Abbott Laboratories | Abuse resistant melt extruded formulation having reduced alcohol interaction |
EP1813276A1 (en) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
FR2897267A1 (fr) | 2006-02-16 | 2007-08-17 | Flamel Technologies Sa | Formes pharmaceutiques multimicroparticulaires pour administration per os |
FR2898056B1 (fr) | 2006-03-01 | 2012-01-20 | Ethypharm Sa | Comprimes resistant a l'ecrasement destines a eviter le detournement illicite |
US20100226855A1 (en) | 2006-03-02 | 2010-09-09 | Spherics, Inc. | Rate-Controlled Oral Dosage Formulations |
MX2008010921A (es) | 2006-03-02 | 2008-09-03 | Mallinckrodt Inc | Procesos para preparar productos de morfinan-6-ona con bajos niveles de compuestos de cetona alfa, beta-insaturados. |
NZ572206A (en) | 2006-03-24 | 2012-02-24 | Auxilium Int Holdings Inc | Process for the preparation of a hot-melt extruded laminate |
AU2007230730B2 (en) | 2006-03-24 | 2013-03-28 | Auxilium International Holdings, Inc. | Stabilized compositions containing alkaline labile drugs |
US20070224637A1 (en) | 2006-03-24 | 2007-09-27 | Mcauliffe Joseph C | Oxidative protection of lipid layer biosensors |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
US9023400B2 (en) | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
WO2007138466A2 (en) | 2006-06-01 | 2007-12-06 | Wockhardt Ltd | Pharmaceutical compositions comprising meloxicam and tramadol combination |
US20070292508A1 (en) | 2006-06-05 | 2007-12-20 | Balchem Corporation | Orally disintegrating dosage forms |
US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
CN101091721A (zh) | 2006-06-22 | 2007-12-26 | 孙明 | 阿胶新剂型的制备方法 |
EP2043613A1 (en) | 2006-07-14 | 2009-04-08 | Fmc Corporation | Solid form |
JP4029109B1 (ja) | 2006-07-18 | 2008-01-09 | タマ生化学株式会社 | ビタミンeとプロリンの複合体粉末及びその製造方法 |
AU2007275033A1 (en) | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophobic abuse deterrent delivery system |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
US8187636B2 (en) | 2006-09-25 | 2012-05-29 | Atlantic Pharmaceuticals, Inc. | Dosage forms for tamper prone therapeutic agents |
KR101400824B1 (ko) | 2006-09-25 | 2014-05-29 | 후지필름 가부시키가이샤 | 레지스트 조성물, 이 레지스트 조성물에 사용되는 수지, 이수지의 합성에 사용되는 화합물, 및 상기 레지스트조성물을 사용한 패턴형성방법 |
EP2079453A1 (en) | 2006-10-10 | 2009-07-22 | Penwest Pharmaceuticals Co. | Robust sustained release formulations |
US20080085304A1 (en) | 2006-10-10 | 2008-04-10 | Penwest Pharmaceuticals Co. | Robust sustained release formulations |
GB0624880D0 (en) | 2006-12-14 | 2007-01-24 | Johnson Matthey Plc | Improved method for making analgesics |
WO2008079404A2 (en) | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
DE102006062120A1 (de) | 2006-12-22 | 2008-06-26 | Grünenthal GmbH | Pharmazeutische Zusammensetzung zur Aknebehandlung |
CA2674536C (en) | 2007-01-16 | 2016-07-26 | Egalet A/S | Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
US20080181932A1 (en) | 2007-01-30 | 2008-07-31 | Drugtech Corporation | Compositions for oral delivery of pharmaceuticals |
CN100579525C (zh) | 2007-02-02 | 2010-01-13 | 东南大学 | 盐酸尼卡地平缓释制剂及其制备方法 |
JP2010518113A (ja) | 2007-02-08 | 2010-05-27 | ケムファーム・インコーポレーテッド | アンフェタミンおよび他の刺激薬の極性親水性プロドラッグ、およびそれらの製造方法および使用方法 |
CN101057849A (zh) | 2007-02-27 | 2007-10-24 | 齐齐哈尔医学院 | 含有盐酸二甲双胍和格列吡嗪的缓释制剂及其制备方法 |
CA2678367C (en) | 2007-03-02 | 2014-07-08 | Farnam Companies, Inc. | Sustained release compositions using wax-like materials |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
EP1980245A1 (en) | 2007-04-11 | 2008-10-15 | Cephalon France | Bilayer lyophilized pharmaceutical compositions and methods of making and using same |
US20080260836A1 (en) | 2007-04-18 | 2008-10-23 | Thomas James Boyd | Films Comprising a Plurality of Polymers |
WO2008132707A1 (en) | 2007-04-26 | 2008-11-06 | Sigmoid Pharma Limited | Manufacture of multiple minicapsules |
WO2008142627A2 (en) | 2007-05-17 | 2008-11-27 | Ranbaxy Laboratories Limited | Multilayered modified release formulation comprising amoxicillin and clavulanate |
US8202542B1 (en) | 2007-05-31 | 2012-06-19 | Tris Pharma | Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings |
CA2687192C (en) | 2007-06-04 | 2015-11-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
CA2690956C (en) | 2007-07-01 | 2017-01-03 | Joseph Peter Habboushe | Combination tablet with chewable outer layer |
US7806296B2 (en) * | 2007-07-10 | 2010-10-05 | Saturday Knight Ltd. | Variable design bathroom accessory |
BRPI0721940A2 (pt) | 2007-07-20 | 2014-03-18 | Abbott Gmbh & Co Kg | Formulações de analgésicos opióides confinados e não-opióides |
WO2009034541A2 (en) | 2007-09-11 | 2009-03-19 | Ranbaxy Laboratories Limited | Controlled release pharmaceutical dosage forms of trimetazidine |
HUE032012T2 (en) | 2007-09-13 | 2017-08-28 | Cima Labs Inc | Anti-Abuse Drug Products |
EP2211760A4 (en) | 2007-10-17 | 2013-09-18 | Axxia Pharmaceuticals Llc | POLYMER DRUG DELIVERY SYSTEMS AND METHODS OF EXTRUSION OF THERMOPLASTIC COMPOUNDS TO PRODUCE THESE SYSTEMS |
KR101607112B1 (ko) | 2007-11-23 | 2016-03-29 | 그뤼넨탈 게엠베하 | 타펜타돌 조성물 |
AU2008347158B8 (en) | 2007-12-06 | 2013-08-22 | Durect Corporation | Oral pharmaceutical dosage forms |
KR20100093591A (ko) | 2007-12-12 | 2010-08-25 | 바스프 에스이 | 활성 구성성분과 중합체 반대이온의 염 |
JP5651818B2 (ja) | 2007-12-17 | 2015-01-14 | パラディン ラブス インコーポレーテッド | 誤用を防止するための放出制御製剤 |
EP2249811A1 (en) | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Pharmaceutical dosage form |
KR100970665B1 (ko) | 2008-02-04 | 2010-07-15 | 삼일제약주식회사 | 알푸조신 또는 그의 염을 함유하는 서방성 정제 |
MX2010009704A (es) | 2008-03-05 | 2010-12-20 | Panacea Biotec Ltd | Composiciones farmaceuticas de liberacion modifcada que comprenden micofenolato y procesos de estas. |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
TWI519322B (zh) | 2008-04-15 | 2016-02-01 | 愛戴爾製藥股份有限公司 | 包含弱鹼性藥物及控制釋放劑型之組合物 |
CA2723438C (en) | 2008-05-09 | 2016-10-11 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
US20110092515A1 (en) | 2008-07-03 | 2011-04-21 | Zhihui Qiu | Melt granulation process |
JP2012501967A (ja) | 2008-08-20 | 2012-01-26 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 調節放出型多粒子のホットメルト押出成形 |
FR2936709B1 (fr) | 2008-10-02 | 2012-05-11 | Ethypharm Sa | Comprimes alcoolo-resistants. |
US20100099696A1 (en) | 2008-10-16 | 2010-04-22 | Anthony Edward Soscia | Tamper resistant oral dosage forms containing an embolizing agent |
EP2362768B1 (en) | 2008-10-27 | 2016-04-20 | Alza Corporation | Extended release oral acetaminophen/tramadol dosage form |
TW201022253A (en) | 2008-11-14 | 2010-06-16 | Portola Pharm Inc | Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low pH and methods of use thereof |
ES2414856T3 (es) | 2008-12-12 | 2013-07-23 | Paladin Labs Inc. | Formulaciones de fármaco narcótico con potencial de adicción disminuido |
AU2009327312A1 (en) | 2008-12-16 | 2011-08-04 | Labopharm Europe Limited | Misuse preventative, controlled release formulation |
EP2389169A1 (en) | 2009-01-26 | 2011-11-30 | Egalet A/S | Controlled release formulations with continuous efficacy |
CA2751627A1 (en) | 2009-02-06 | 2010-08-12 | Egalet Ltd. | Pharmaceutical compositions resistant to abuse |
KR101571198B1 (ko) | 2009-03-18 | 2015-11-23 | 에보니크 룀 게엠베하 | 중성 비닐 중합체 및 부형제를 포함하는 코팅을 이용하는, 에탄올의 영향에 대한 내성을 갖는 제어 방출 제약 조성물 |
EP2246063A1 (en) | 2009-04-29 | 2010-11-03 | Ipsen Pharma S.A.S. | Sustained release formulations comprising GnRH analogues |
GB0909680D0 (en) | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
WO2010149169A2 (en) | 2009-06-24 | 2010-12-29 | Egalet A/S | Controlled release formulations |
WO2011008298A2 (en) | 2009-07-16 | 2011-01-20 | Nectid, Inc. | Novel axomadol dosage forms |
BR112012001244A2 (pt) | 2009-07-22 | 2020-12-08 | Gruünenthal Gmbh | Forma de dosagem resitente à adulteração, seu processo de produção, e embalagem contendo tal forma |
WO2011009602A1 (en) | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Hot-melt extruded controlled release dosage form |
AU2010300641B2 (en) | 2009-09-30 | 2016-03-17 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
EP2506838A1 (en) | 2009-12-01 | 2012-10-10 | Noven Pharmaceuticals, INC. | Transdermal testosterone device and delivery |
US9579285B2 (en) | 2010-02-03 | 2017-02-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of an extruder |
GB201003731D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
SG10201504529WA (en) | 2010-03-09 | 2015-07-30 | Alkermes Pharma Ireland Ltd | Alcohol Resistant Enteric Pharmaceutical Compositions |
EP2552425B1 (en) | 2010-04-02 | 2016-07-27 | Buzzz Pharmaceuticals Limited | Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists |
AU2011236548A1 (en) | 2010-04-07 | 2012-11-01 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
GB201006200D0 (en) | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
WO2011133980A1 (en) | 2010-04-23 | 2011-10-27 | Subhash Desai | Therapeutic formulation for reduced drug side effects |
US20130059010A1 (en) | 2010-05-14 | 2013-03-07 | Ethypharm | Alcohol-resistant oral pharmaceutical form |
FR2960775A1 (fr) | 2010-06-07 | 2011-12-09 | Ethypharm Sa | Microgranules resistants au detournement |
AR082862A1 (es) | 2010-09-02 | 2013-01-16 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico |
RU2604676C2 (ru) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль |
WO2012028317A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polymer |
US20120202838A1 (en) | 2010-11-04 | 2012-08-09 | Abbott Laboratories | Drug formulations |
US20120231083A1 (en) | 2010-11-18 | 2012-09-13 | The Board Of Trustees Of The University Of Illinois | Sustained release cannabinoid medicaments |
GB201020895D0 (en) | 2010-12-09 | 2011-01-26 | Euro Celtique Sa | Dosage form |
JP5638151B2 (ja) | 2010-12-23 | 2014-12-10 | パーデュー、ファーマ、リミテッド、パートナーシップ | 不正加工抵抗性の(tamperresistant)固形経口剤形 |
CA2827273A1 (en) | 2011-02-17 | 2012-08-23 | QRxPharma Ltd. | Technology for preventing abuse of solid dosage forms |
SI3287123T1 (sl) | 2011-03-04 | 2020-07-31 | Gruenenthal Gmbh | Vodna farmacevtska formulacija tapentadola za peroralno uporabo |
WO2012146383A1 (en) | 2011-04-29 | 2012-11-01 | Grünenthal GmbH | Tapentadol for preventing and treating depression and anxiety |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
ES2628303T3 (es) | 2011-06-01 | 2017-08-02 | Fmc Corporation | Formas de dosis sólidas de liberación controlada |
EP2726065A4 (en) | 2011-06-30 | 2014-11-26 | Neos Therapeutics Lp | MISS-BROKEN MEDICINAL PRODUCTS |
BR112014002022A2 (pt) | 2011-07-29 | 2017-02-21 | Gruenenthal Gmbh | comprimido resistente à violação proporcionando liberação de fármaco imediata |
PT2736497T (pt) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Comprimido resistente a adulteração proporcionando libertação imediata de fármaco |
FR2979242A1 (fr) | 2011-08-29 | 2013-03-01 | Sanofi Sa | Comprime contre l'usage abusif, a base de paracetamol et d'oxycodone |
CN103998025A (zh) | 2011-10-06 | 2014-08-20 | 格吕伦塔尔有限公司 | 包含阿片样物质激动剂和阿片样物质拮抗剂的防篡改口服药物剂型 |
MX349725B (es) | 2011-11-17 | 2017-08-10 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica oral a prueba de manipulacion que comprende un agente antagonista y/o aversivo opioide, oxido de polialquileno y un polimero anionico. |
CN104010630A (zh) | 2011-12-09 | 2014-08-27 | 普渡制药公司 | 包含聚(ε-己内酯)和聚氧乙烯的药物剂型 |
WO2013127830A1 (en) | 2012-02-28 | 2013-09-06 | Grünenthal GmbH | Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant |
CA2864949A1 (en) | 2012-02-28 | 2013-09-06 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
PE20142320A1 (es) | 2012-03-02 | 2015-01-16 | Rhodes Pharmaceuticals Lp | Formulaciones de liberacion inmediata resistentes a la manipulacion |
ES2692944T3 (es) | 2012-04-18 | 2018-12-05 | Grünenthal GmbH | Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis |
WO2013167735A1 (en) | 2012-05-11 | 2013-11-14 | Grünenthal GmbH | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
CA2880163A1 (en) | 2012-08-01 | 2014-02-06 | Acura Pharmaceuticals, Inc. | Stabilization of one-pot methamphetamine synthesis systems |
KR20150047493A (ko) | 2012-08-27 | 2015-05-04 | 에보닉 인두스트리에스 아게 | 에탄올의 영향에 대해 내성을 갖는 위 내성 제약 또는 기능식품 조성물 |
AU2012388441B2 (en) | 2012-08-27 | 2017-07-27 | Evonik Operations Gmbh | Pharmaceutical or nutraceutical composition with sustained release characteristic and with resistance against the influence of ethanol |
JP5775223B2 (ja) | 2012-09-05 | 2015-09-09 | テイカ製薬株式会社 | 口腔内速崩壊性錠剤用造粒物 |
EP2906202A4 (en) | 2012-10-15 | 2016-04-27 | Isa Odidi | DRUG FORMULATIONS FOR ORAL ADMINISTRATION |
BR112015022567A2 (pt) | 2013-03-15 | 2017-07-18 | Mallinckrodt Llc | composições compreendendo um opioide e um ingrediente farmacêutico ativo adicional para início rápido e duração prolongada de analgesia que podem ser administradas sem alimento |
US10420729B2 (en) | 2013-03-15 | 2019-09-24 | R.P. Scherer Technologies, Llc | Abuse resistant capsule |
MX371432B (es) | 2013-05-29 | 2020-01-30 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido que contiene una o mas particulas. |
MX2015016254A (es) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal. |
CA2817728A1 (en) | 2013-05-31 | 2014-11-30 | Pharmascience Inc. | Abuse deterrent immediate release formulation |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
US9770514B2 (en) | 2013-09-03 | 2017-09-26 | ExxPharma Therapeutics LLC | Tamper-resistant pharmaceutical dosage forms |
WO2015048597A1 (en) | 2013-09-30 | 2015-04-02 | Daya Drug Discoveries, Inc. | Prevention of illicit methamphetamine manufacture from pseudoephedrine using food flavor excipients |
US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
WO2015103379A1 (en) | 2013-12-31 | 2015-07-09 | Kashiv Pharma, Llc | Abuse-resistant drug formulations |
US10632113B2 (en) | 2014-02-05 | 2020-04-28 | Kashiv Biosciences, Llc | Abuse-resistant drug formulations with built-in overdose protection |
MX2016010433A (es) | 2014-02-12 | 2016-09-22 | Genentech Inc | Anticuerpos anti-jagged1 y metodos de uso. |
US20160089439A1 (en) | 2014-09-28 | 2016-03-31 | Satara Pharmaceuticals, LLC | Prevention of Illicit Manufacutre of Methamphetamine from Pseudoephedrine Using Food Flavor Excipients |
CN107889459A (zh) | 2015-04-24 | 2018-04-06 | 格吕伦塔尔有限公司 | 具有立即释放和对溶剂萃取的抗性的抗篡改剂型 |
US20170296476A1 (en) | 2016-04-15 | 2017-10-19 | Grünenthal GmbH | Modified release abuse deterrent dosage forms |
-
2014
- 2014-11-26 CN CN201480064700.5A patent/CN105934241B/zh active Active
- 2014-11-26 MX MX2016006552A patent/MX371372B/es active IP Right Grant
- 2014-11-26 WO PCT/EP2014/075618 patent/WO2015078891A1/en active Application Filing
- 2014-11-26 CA CA2931553A patent/CA2931553C/en active Active
- 2014-11-26 AU AU2014356581A patent/AU2014356581C1/en active Active
- 2014-11-26 JP JP2016534227A patent/JP6480936B2/ja active Active
- 2014-11-26 BR BR112016010482-0A patent/BR112016010482B1/pt active IP Right Grant
- 2014-11-26 EP EP14802674.3A patent/EP3073994A1/en active Pending
-
2016
- 2016-04-14 IL IL245137A patent/IL245137B/en active IP Right Grant
- 2016-05-25 US US15/164,326 patent/US10449547B2/en active Active
- 2016-10-28 HK HK16112459.1A patent/HK1224189A1/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000513333A (ja) * | 1996-05-14 | 2000-10-10 | アルカームズ コントロールド セラピューティックス,インコーポレイテッド | ポリマーを基剤とした制御された放出デバイスの製造方法 |
JP2004143071A (ja) * | 2002-10-23 | 2004-05-20 | Hosokawa Funtai Gijutsu Kenkyusho:Kk | 薬物含有複合粒子の製造方法および薬物含有複合粒子 |
WO2011059074A1 (ja) * | 2009-11-13 | 2011-05-19 | 森六ケミカルズ株式会社 | 微粉末の製造方法および同方法で製造された微粉末 |
WO2013025449A1 (en) * | 2011-08-16 | 2013-02-21 | Merck Sharp & Dohme Corp. | Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions |
JP2013155124A (ja) * | 2012-01-30 | 2013-08-15 | Moriroku Chemicals Co Ltd | 医薬品の原末及びその製造方法 |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 99, no. 1, JPN6018031232, 2 June 2009 (2009-06-02), pages 196 - 208, ISSN: 0003915142 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018172288A (ja) * | 2017-03-31 | 2018-11-08 | ライオン株式会社 | 粉砕物及び錠剤の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2931553A1 (en) | 2015-06-04 |
HK1224189A1 (zh) | 2017-08-18 |
CN105934241B (zh) | 2020-06-05 |
MX371372B (es) | 2020-01-28 |
US20160263032A1 (en) | 2016-09-15 |
US10449547B2 (en) | 2019-10-22 |
IL245137B (en) | 2021-02-28 |
BR112016010482A2 (ja) | 2017-08-08 |
MX2016006552A (es) | 2016-08-03 |
AU2014356581C1 (en) | 2020-05-28 |
BR112016010482B1 (pt) | 2022-11-16 |
WO2015078891A1 (en) | 2015-06-04 |
CA2931553C (en) | 2022-01-18 |
AU2014356581B2 (en) | 2019-12-05 |
JP6480936B2 (ja) | 2019-03-13 |
CN105934241A (zh) | 2016-09-07 |
EP3073994A1 (en) | 2016-10-05 |
AU2014356581A1 (en) | 2016-05-12 |
IL245137A0 (en) | 2016-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9579285B2 (en) | Preparation of a powdery pharmaceutical composition by means of an extruder | |
Patil et al. | Hot-melt extrusion: from theory to application in pharmaceutical formulation | |
KR101690094B1 (ko) | 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법 | |
KR101116518B1 (ko) | 다중입자 | |
JP6077713B2 (ja) | ホットメルト断片化押出機およびプロセス | |
JP6480936B2 (ja) | クライオミリングによる粉末状医薬組成物の調製 | |
Ayyub et al. | Effect of melt extrudability and melt binding efficiency of polyvinyl caprolactam polyvinyl acetate polyethylene glycol graft copolymer (Soluplus®) on release pattern of hydrophilic and high dose drugs | |
CN112585192B (zh) | 纤维素粉末、其用途及片剂 | |
EP3445558B1 (en) | Fractional lobe processor, and related process for hot melt extrusion | |
TW202037366A (zh) | 纖維素粉末、錠劑及錠劑之製造方法 | |
Maniruzzaman et al. | Hot-melt extrusion (HME): from process to pharmaceutical applications | |
CN117120036A (zh) | 低溶性药物的连续热熔融制粒方法 | |
Maniruzzaman et al. | Hot-melt extrusion: a versatile technology | |
Kinikar et al. | Recent Advances in Hot Melt Extrusion and its Applications | |
Davis Jr et al. | Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs | |
CN109069652A (zh) | 用于熔体挤出应用的聚合物的粒度和分布 | |
CN118234388A (zh) | 可通过连续熔融造粒获得的高效力颗粒 | |
WO2023049861A1 (en) | High-dose compressible dosage forms manufactured by simultaneous melt-coating and melt-granulation of active pharmaceutical ingredients | |
CN111388428A (zh) | 一种托吡酯缓释制剂、制备方法及其应用 | |
GRANULATION | IMPACT OF SCREW CONFIGURATION ON THE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180815 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181024 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181226 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190208 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6480936 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |